Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004Rritual Superfoods Ready to Launch Amazon Store in USAAtai Life Sciences Is Setting The Stage For The Largest IPO The Psychedelics Sector Has Seen To DateEntheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available fMajor U.S. States Are Taking A Serious Look At Decriminalizing Psychedelic Compounds For The Treatment Of Mental IllnessMAPS Canada Is Leading The Global Charge To Commercialize Psychedelic TherapiesBetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of DirectorsMindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic MedicineTryp Therapeutics Partners with Alcami for Proprietary FormulationsHAVN Life Secures Production & Supply Agreement to Expand Retail Product OfferingsCybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery MechanismsNuminus Wellness Is One Of The Shining Stars Of The Psychedelic SectorPsychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream MediaMAPS Canada Is Leading The Way For Psychedelic Use Cases In Modern MedicineRritual Superfoods Initiates Canadian Retail Growth Strategy Signing with Ultimate Sales CanadaNuminus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for SevTryp Therapeutics Partners with Clinlogix for Clinical Trial SupportTryp Therapeutics Partners with Fluence for Psychotherapy DesignTryp Therapeutics Announces Q2 2021 Financial ResultsRritual Announces CROSSMARK Partnership to Optimize Retail Growth
Back

MindMed Inks Deal With Switzerland University For Rights On LSD Research

Apr 7, 2020 • 1:04 PM EDT
1 MIN READ  •  By Anthony Varrell
Share Share - Facebook Share - Twitter

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s University Hospital Basel.

Exploring High-Dose LSD Treatment for Anxiety

MindMed CEO JR Rahn told Benzinga that much emphasis has been placed on psilocybin in recent years as a psychedelic therapy model, but the potential safety and efficacy of LSD in hallucinogenic psychotherapy may provide an even greater promise for patients.

“Over the past decade we have amassed the largest collection of clinical trials around LSD,” said Matthias Liechti, who heads the psychedelics research lab at University Hospital Basel. “We have been studying the pharmacology and potential medical uses of LSD and other psychedelics for many years in the laboratory, in patients, and in healthy volunteers.”

MindMed has special interest in an Phase 2 trial on high-dose LSD treatment for anxiety currently being conducted by Liechti’s lab. The company will also work under the direction of Liechti to continue developing therapy with LSD micro-dose as potential treatment for adult ADHD.

MindMed hopes to leverage the impactful data and clinical trials Liecthi and his team have “diligently executed on in LSD for 10 plus years,” the company said.

Through future commercial clinical drug trials, the goal is to turn LSD into an FDA approved medicine as a way to treat mental illnesses.

Share Share - Facebook Share - Twitter

Tags

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link